Antimicrobial stewardship interventions for Staphylococcus aureus bacteremia: cost analysis of alternative therapies

Document Type

Poster Presentation

Publication Date



Staphylococcus aureus bacteremia (SAB) is a significant cost burden to the US Health System. Clinical management of SAB becomes challenging in patients who are not candidates for or fail first line therapies such as vancomycin (V), semisynthetic penicillin’s (SSP) or cefazolin (C). Alternative agents for SAB includes ceftaroline (CPT) and daptomycin (DAP), however outcomes data are limited. The purpose of this study was to assess inpatient pharmacy drug costs of alternative antimicrobials for treatment of SAB in patients who cannot tolerate or fail recommended therapies from the hospital perspective.


Poster presented at IDWeek in New Orleans, Louisiana, on October 28, 2016.

This document is currently not available here.

Additional Files